Short-chain fatty acids in Huntington's disease: Mechanisms of action and their therapeutic implications
Pharmacology Biochemistry and Behavior · 2025
DOI: 10.1016/j.pbb.2025.173972 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Biochemistry and Behavior, 2025. Verfasst von Mohamed J Saadh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Middle East University, Amman 11831, Jordan. Electronic address: msaadeh@meu.edu.jo. Hauptthemen laut MEDLINE: Huntington Disease, Fatty Acids, Volatile. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 256 Literaturangaben.
Abstract (Originalsprache)
Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and emotional instability, primarily resulting from the abnormal accumulation of mutant huntingtin protein. Growing research highlights the role of intestinal microbiota and their metabolites, particularly short-chain fatty acids (SCFAs), in modulating HD progression. SCFAs, including acetate, propionate, and butyrate, are produced by gut bacteria through dietary fiber fermentation and are recognized for their neuroprotective properties. Evidence suggests that SCFAs regulate neuroinflammation, neuronal communication, and metabolic functions within the central nervous system (CNS). In HD, these compounds may support neuronal health, reduce oxidative stress, and enhance blood-brain barrier (BBB) integrity. Their mechanisms of action involve binding to G-protein-coupled receptors (GPCRs) and modulating gene expression through epigenetic pathways, underscoring their therapeutic potential. This analysis examines the significance of SCFAs in HD, emphasizing the gut-brain axis and the benefits of dietary interventions aimed at modifying gut microbiota composition and promoting SCFA production. Further research into these pathways may pave the way for novel HD management strategies and improved therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Middle East University, Amman 11831, Jordan. Electronic address: msaadeh@meu.edu.jo.
- College of Pharmacy, Alnoor University, Mosul, Iraq.
- Ahl Al Bayt University, Kerbala, Iraq.
- Marwadi University Research Center, Department of Microbiology, Faculty of Science, Marwadi University, Rajkot 360003, Gujarat, India.
- Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Pharmaceutical Chemistry, NIMS Institute of Pharmacy, NIMS University, Rajasthan, Jaipur,302131, India.
Zitieren
APA
Saadh, M. J., Ahmed, H. H., Kareem, R. A., Sanghvi, G., Ganesan, S., Agarwal, M., Kaur, P., Taher, W. M., Alwan, M., Jawad, M. J., & Hamad, A. K. (2025). Short-chain fatty acids in Huntington's disease: Mechanisms of action and their therapeutic implications. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2025.173972
Vancouver
Saadh MJ, Ahmed HH, Kareem RA, Sanghvi G, Ganesan S, Agarwal M, et al. Short-chain fatty acids in Huntington's disease: Mechanisms of action and their therapeutic implications. Pharmacology Biochemistry and Behavior. 2025. doi:10.1016/j.pbb.2025.173972
BibTeX
@article{Saadh2025,
author = {Saadh, Mohamed J and Ahmed, Hanan Hassan and Kareem, Radhwan Abdul and Sanghvi, Gaurav and Ganesan, Subbulakshmi and Agarwal, Mohit and Kaur, Parjinder and Taher, Waam Mohammed and Alwan, Mariem and Jawad, Mahmood Jasem and Hamad, Atheer Khdyair},
title = {Short-chain fatty acids in Huntington's disease: Mechanisms of action and their therapeutic implications},
journal = {Pharmacology Biochemistry and Behavior},
year = {2025},
doi = {10.1016/j.pbb.2025.173972}
}
EUVIMED